Cutera Announces Appointment of New CEO

Cutera Inc., a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, announced that David H. Mowry, 56, has been named chief executive officer, effective immediately. Mowry has also been appointed to the company’s Board of Directors. Mowry succeeds Jason Richey, who served as interim CEO since January 7, 2019.
 
Mowry is a career medical device executive with successful leadership assignments across multiple market segments. Most recently, Mowry served as president and CEO of Vyaire Medical, a privately-held global respiratory care business with revenues exceeding $750 million. While serving at Vyaire, Mowry led the efforts to carve-out four separate divisions from Becton-Dickinson and Company (BDX), following its acquisition of CareFusion, combining the units into a standalone, singularly-focused Respiratory Care company. Prior to Vyaire, Mowry was the president and CEO of Tornier Inc., a publicly-traded leader in orthopedic extremities solutions acquired by Wright Medical (WMGI) in October 2015 for approximately $1.6 billion. While leading Tornier, Mowry consistently delivered above-market growth through strong commercial execution, portfolio development, and differentiated service to Tornier’s clinician customers. Prior to Tornier, Mowry served as president of Covidien’s Neurovascular Division, a recognized leader in the hemorrhagic and ischemic stroke interventional device markets. Mowry received a BS in engineering from The United States Military Academy at West Point.
 
“We are pleased to welcome David Mowry as Cutera’s CEO,” commented J. Daniel Plants, chairman of the Board of Directors. “Dave is a highly regarded leader in the medical device industry, with a proven track record of building great businesses and creating shareholder value. We’re confident that Dave’s vision, operational discipline, and commercial acumen make him the ideal leader for Cutera, and we’re excited to leverage his experience to help Cutera reach the next level.”
 
Plants also commented on the success of the company’s leadership in effectuating a successful CEO transition during the past six months. “On behalf of Cutera’s Board of Directors, I would like to thank Jason Richey for his outstanding efforts serving as our interim CEO. Under Jason’s direction, Cutera’s senior management has put in motion a number of important initiatives and stabilized the business, as evidenced by the preliminary financial results which we are also issuing today—exceeding revenue expectations in both quarters under his watch. Jason is a talented leader and, in recognition of his many contributions, we have promoted him to the role of president, the first executive to hold this title at Cutera. Finally, our search committee, comprised of directors Gregory Barrett and Timothy O’Shea, deserves commendation for its thorough process, which culminated in the identification and recruitment of Dave Mowry as our next CEO.”
 
“I am delighted to have the opportunity to lead Cutera, a company with an exceptionally strong product portfolio and a reputation for delivering differentiated technology developed with the clinician customer in mind. The company’s unique, singular focus on the aesthetics market provides it with the ideal scale and scope to win,” commented Mowry. “I am especially excited to work with the talented team at Cutera to deliver sustainable growth and improved profitability while, most importantly, continuing to deliver market-leading technology to our valued customers. I am confident in our ability to position Cutera for long-term success and look forward to working together to achieve our full potential.”
 
Cutera also announced that its preliminary, unaudited financial results for the quarter ended June 30, 2019 exceeded consensus growth estimates and its own revenue forecast. The company plans to release full second quarter financial results as scheduled on August 8, 2019 after market close.